Literature DB >> 2838550

Tumor necrosis factor-induced activation of peritoneal macrophages is regulated by prostaglandin E2 and cAMP.

V Lehmmann1, B Benninghoff, W Dröge.   

Abstract

Human rTNF-alpha stimulates the metabolism of murine peritoneal macrophages as demonstrated by an increased consumption of arginine and an increased release of L-ornithine. This TNF-mediated effect is augmented by several substances that raise the intracellular concentration of cAMP, including PGE2, cholera toxin, and dibutyryl-cAMP. TNF also stimulates the endogenous production of PGE2 in cultures of peritoneal macrophages. The addition of the cyclo-oxygenase inhibitor, indomethacin, suppresses the TNF-mediated metabolic activation of macrophages, and this suppressive effect of indomethacin is overcome if exogenous PGE2 or cholera toxin is added to the culture. Taken together, the experiments indicate that the TNF-induced production of PGE2 and the PGE2-induced increase of the intracellular cAMP concentration are essential elements of an auto-regulatory loop that controls the magnitude of the TNF-mediated effect in the macrophage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838550

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.

Authors:  D Pyeon; F J Diaz; G A Splitter
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.

Authors:  D Vial; L Arbibe; N Havet; C Dumarey; B Vargaftig; L Touqui
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

3.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

Authors:  O Morteau; S G Morham; R Sellon; L A Dieleman; R Langenbach; O Smithies; R B Sartor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in rats.

Authors:  S B Holmberg; P L Naredi; G O Lindnér; I H Karlberg; P L Daneryd; L M Karlsson; A Pettersson; U Stenram; L R Hafström
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.

Authors:  M Watanabe; M Yamada; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 6.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Role of elevated monocyte transforming growth factor beta (TGF beta) production in posttrauma immunosuppression.

Authors:  C L Miller-Graziano; G Szabo; K Griffey; B Mehta; K Kodys; D Catalano
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

8.  Staphylococcal glycocalyx activates macrophage prostaglandin E2 and interleukin 1 production and modulates tumor necrosis factor alpha and nitric oxide production.

Authors:  R D Stout; Y Li; A R Miller; D W Lambe
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis.

Authors:  T M Horton; T S Ranheim; L Aquino; D I Kusher; S K Saha; C F Ware; W S Wold; L R Gooding
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Human macrophages acquire a hyporesponsive state of tumor necrosis factor alpha production in response to successive Mycobacterium avium serovar 4 stimulation.

Authors:  H Gan; G W Newman; H G Remold
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.